Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.6558.0886
Address
Level 3 101 St George’s Terrace Perth, Western Australia (WA) 6000
Description
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.28 - 1.75
Trade Value (12mth)
AU$1,552.00
1 week
-13.7%
1 month
103.23%
YTD
-32.98%
1 year
-60.87%
All time high
20453.10
EPS 3 yr Growth
-61.800%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-21.40%
ROIC
-16.50%
Interest Coverage
-89.60
Quick Ratio
0.10
Shares on Issue (Fully Dilluted)
11m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
16 July 24 |
Zelira secures leading patents for HOPE 1 and HOPE 2
×
Zelira secures leading patents for HOPE 1 and HOPE 2 |
11 July 24 |
ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
×
ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting |
04 July 24 |
Zelira Receives USD$1.4Million Unsecured Loan from Chairman
×
Zelira Receives USD$1.4Million Unsecured Loan from Chairman |
01 July 24 |
ZLD secures US$1.4M unsecured Chairman loan facility
×
ZLD secures US$1.4M unsecured Chairman loan facility |
23 May 24 |
HOPE SPV receives US$681,000 third tranche of funding
×
HOPE SPV receives US$681,000 third tranche of funding |
29 April 24 |
March 2024 Quarterly Activities Report
×
March 2024 Quarterly Activities Report |
29 April 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
15 April 24 |
Zelira receives $919,000 R&D Tax Incentive Scheme Refund
×
Zelira receives $919,000 R&D Tax Incentive Scheme Refund |
22 February 24 |
Appendix 4D & FY24 Interim Financial Report
×
Appendix 4D & FY24 Interim Financial Report |
31 January 24 |
December 2023 Quarterly Activities Report
×
December 2023 Quarterly Activities Report |
31 January 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
29 January 24 |
Notification regarding unquoted securities - ZLD
×
Notification regarding unquoted securities - ZLD |
23 January 24 |
Notification of cessation of securities - ZLD
×
Notification of cessation of securities - ZLD |
11 January 24 |
Change of Auditor
×
Change of Auditor |
08 January 24 |
HOPE SPV receives US$819,000 second tranche of funding
×
HOPE SPV receives US$819,000 second tranche of funding |
24 November 23 |
Notification regarding unquoted securities - ZLD
×
Notification regarding unquoted securities - ZLD |
24 November 23 |
Change of Director's Interest Notice x 5
×
Change of Director's Interest Notice x 5 |
23 November 23 |
Proposed issue of securities - ZLD
×
Proposed issue of securities - ZLD |
15 November 23 |
2023 Annual General Meeting Presentation
×
2023 Annual General Meeting Presentation |
15 November 23 |
Results of Meeting
×
Results of Meeting |
13 November 23 |
Notification of cessation of securities - ZLD
×
Notification of cessation of securities - ZLD |
03 November 23 |
Notification of cessation of securities - ZLD
×
Notification of cessation of securities - ZLD |
31 October 23 |
September 2023 Quarterly Activities Report
×
September 2023 Quarterly Activities Report |
31 October 23 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
16 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.